Human Immunodeficiency Virus (HIV)

Efavirenz, a non-nucleoside analogue inhibitor of the reverse transcriptase, has become commonly used in highly active antiretroviral combination therapy in the treatment of HIV infection due to its ease of once daily dosing. However, there are early and serious side effects, such as acute psychosis resembling reactions to LSD intake, as well as nightmares occurring for several days up to 4 weeks after the start of therapy.[1] Efavirenz should be avoided in patients with a history of mental illness, such as schizophrenia.

References